RU2729011C2 - Производные fgf21 и их применения - Google Patents

Производные fgf21 и их применения Download PDF

Info

Publication number
RU2729011C2
RU2729011C2 RU2017125050A RU2017125050A RU2729011C2 RU 2729011 C2 RU2729011 C2 RU 2729011C2 RU 2017125050 A RU2017125050 A RU 2017125050A RU 2017125050 A RU2017125050 A RU 2017125050A RU 2729011 C2 RU2729011 C2 RU 2729011C2
Authority
RU
Russia
Prior art keywords
ethoxy
amino
fgf21
oxo
ala
Prior art date
Application number
RU2017125050A
Other languages
English (en)
Russian (ru)
Other versions
RU2017125050A3 (enExample
RU2017125050A (ru
Inventor
Биргит ВЕЧОРЕК
Тина Мёллер ТАГМОСЕ
Кристиан САСС-ЭРУМ
Биргитта АНДЕРСЕН
Йёрген ОЛСЕН
Original Assignee
Ново Нордиск А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ново Нордиск А/С filed Critical Ново Нордиск А/С
Publication of RU2017125050A publication Critical patent/RU2017125050A/ru
Publication of RU2017125050A3 publication Critical patent/RU2017125050A3/ru
Application granted granted Critical
Publication of RU2729011C2 publication Critical patent/RU2729011C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2017125050A 2014-12-23 2015-12-22 Производные fgf21 и их применения RU2729011C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199935.9 2014-12-23
EP14199935 2014-12-23
PCT/EP2015/080969 WO2016102562A1 (en) 2014-12-23 2015-12-22 Fgf21 derivatives and uses thereof

Publications (3)

Publication Number Publication Date
RU2017125050A RU2017125050A (ru) 2019-01-25
RU2017125050A3 RU2017125050A3 (enExample) 2019-06-06
RU2729011C2 true RU2729011C2 (ru) 2020-08-03

Family

ID=52130150

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017125050A RU2729011C2 (ru) 2014-12-23 2015-12-22 Производные fgf21 и их применения

Country Status (24)

Country Link
US (3) US9744213B2 (enExample)
EP (1) EP3236991B1 (enExample)
JP (1) JP6727210B2 (enExample)
KR (1) KR102427527B1 (enExample)
CN (1) CN107108709B (enExample)
AR (1) AR103246A1 (enExample)
AU (1) AU2015371056B2 (enExample)
DK (1) DK3236991T3 (enExample)
ES (1) ES2742503T3 (enExample)
HK (1) HK1246156B (enExample)
HR (1) HRP20191292T1 (enExample)
HU (1) HUE044783T2 (enExample)
IL (1) IL252438B (enExample)
MX (1) MX377044B (enExample)
MY (1) MY181181A (enExample)
PL (1) PL3236991T3 (enExample)
PT (1) PT3236991T (enExample)
RS (1) RS59154B1 (enExample)
RU (1) RU2729011C2 (enExample)
SA (1) SA517381673B1 (enExample)
SI (1) SI3236991T1 (enExample)
TW (2) TWI708781B (enExample)
WO (1) WO2016102562A1 (enExample)
ZA (1) ZA201703768B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102433503B1 (ko) 2016-05-24 2022-08-18 노보 노르디스크 에이/에스 Mic-1 화합물 및 이것의 사용
CN106421753A (zh) * 2016-10-19 2017-02-22 哈尔滨医科大学 重组人成纤维细胞生长因子‑21在制备预防和治疗缺血性心律失常药物中的应用
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
WO2019043457A2 (en) 2017-09-04 2019-03-07 89Bio Ltd. CONJUGATES OF MUTANT PEPTIDE FGF-21 AND USES THEREOF
KR20210027426A (ko) 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 Fgf21 제제
US11427623B1 (en) 2019-05-28 2022-08-30 89Bio Ltd. Methods of treatment using mutant FGF-21 peptide conjugates
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
EP4089108A1 (en) 2021-05-11 2022-11-16 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
US20240279297A1 (en) 2021-05-11 2024-08-22 Cytoki Pharma Aps Therapeutic derivatives of interleukin-22
KR102631925B1 (ko) * 2021-06-10 2024-02-01 토드제약 주식회사 신규 fgf21 변이체 개발 및 이의 생산기법과 용도
WO2023284822A1 (en) * 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders
JP2024531980A (ja) * 2021-09-08 2024-09-03 リートー ラボラトリーズ カンパニー リミテッド Ｆｇｆ２１変異タンパク質及びその応用
MA71385A (fr) 2022-07-08 2025-04-30 Novo Nordisk A/S Composés isvd hautement puissants capables de remplacer fviii(a)
US12098400B2 (en) 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
AR132255A1 (es) 2023-03-30 2025-06-11 Novo Nordisk As Compuestos de fusión y usos de estos
CN121194798A (zh) * 2023-05-12 2025-12-23 诺和诺德股份有限公司 长效生长激素受体拮抗剂及其用途
KR20250039299A (ko) 2023-09-11 2025-03-20 노보 노르디스크 에이/에스 항-il-6 도메인 항체
CN118307684B (zh) * 2024-06-11 2024-10-18 北京志道生物科技有限公司 一种经脂肪酸链修饰的glp-1-fgf21融合蛋白及其制备方法和应用
WO2026012311A1 (zh) * 2024-07-08 2026-01-15 浙江道尔生物科技有限公司 Fgf21衍生物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011154349A2 (en) * 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
WO2012010553A1 (en) * 2010-07-20 2012-01-26 Novo Nordisk A/S N-terminal modified fgf21 compounds
RU2525393C2 (ru) * 2009-01-23 2014-08-10 Ново Нордиск А/С Производные fgf21 со связующим альбумина а-в-с-d-e- и их применение

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
EP1329227A1 (en) 2002-01-22 2003-07-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells
ES2371072T3 (es) 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
EP1670515A2 (en) 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
TW200522976A (en) 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
EP2270163A1 (en) 2003-12-10 2011-01-05 Eli Lilly and Company Muteins of fibroblast growth factor 21
CN101665538A (zh) 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
WO2005091944A2 (en) 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
PL1751184T3 (pl) 2004-05-13 2010-02-26 Lilly Co Eli Białka fuzyjne FGF-21
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
ES2542228T3 (es) 2004-07-08 2015-08-03 Novo Nordisk A/S Marcas de prolongación polipeptídica que comprenden un resto de tetrazol
EP1789443A1 (en) 2004-09-02 2007-05-30 Eli Lilly And Company Muteins of fibroblast growth factor 21
BRPI0514790A (pt) 2004-09-02 2008-06-24 Lilly Co Eli muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
JP2008522617A (ja) 2004-12-14 2008-07-03 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
EP1846019A2 (en) 2005-01-21 2007-10-24 Eli Lilly And Company Method for treating cardiovascular disease
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US20100022446A1 (en) 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
SI2068909T1 (sl) 2007-03-30 2012-09-28 Ambrx Inc Modificirani fgf-21 polipeptidi in njihova uporaba
US20110034373A1 (en) 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CN100587073C (zh) 2008-03-24 2010-02-03 吉林农大生物反应器工程有限公司 人成纤维细胞生长因子-21的重组表达
SG193860A1 (en) * 2008-06-04 2013-10-30 Amgen Inc Fgf21 mutants and uses thereof
NZ592009A (en) * 2008-10-10 2012-11-30 Amgen Inc Fgf21 mutants and uses thereof
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
BRPI1011404B1 (pt) 2009-05-05 2022-05-03 Amgen Inc Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
US20120035099A1 (en) 2009-06-11 2012-02-09 Novo Nordisk A/S Fgf21 analogues and derivatives
CN102802657A (zh) 2009-06-11 2012-11-28 诺沃-诺迪斯克有限公司 用于治疗2型糖尿病的glp-1和fgf21组合
WO2013033452A2 (en) * 2011-08-31 2013-03-07 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
MX2015002985A (es) * 2012-09-07 2015-06-22 Sanofi Sa Proteinas de fusion para el tratamiento de un sindrome metabolico.
MX383664B (es) * 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2525393C2 (ru) * 2009-01-23 2014-08-10 Ново Нордиск А/С Производные fgf21 со связующим альбумина а-в-с-d-e- и их применение
WO2011154349A2 (en) * 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
WO2012010553A1 (en) * 2010-07-20 2012-01-26 Novo Nordisk A/S N-terminal modified fgf21 compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HECHT R. et al., Rational-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes, PLOS ONE, 2012, v. 7, p. e49345. *
XU J. et al., Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation, BIOCONJUGATE CHEM., 2013, v. 24, p. 915-925. *
XU J. et al., Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation, BIOCONJUGATE CHEM., 2013, v. 24, p. 915-925. HECHT R. et al., Rational-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes, PLOS ONE, 2012, v. 7, p. e49345. *
YIE J. et al., FGF21 N- and C-terminal play different roles in receptor interaction and activation, FEBS LETTERS, 2009, v. 583, p. 19-24. *

Also Published As

Publication number Publication date
PL3236991T3 (pl) 2019-12-31
MX2017007458A (es) 2017-08-10
JP6727210B2 (ja) 2020-07-22
KR20170095256A (ko) 2017-08-22
TWI708781B (zh) 2020-11-01
CA2972128A1 (en) 2016-06-30
HUE044783T2 (hu) 2019-11-28
US20180140673A1 (en) 2018-05-24
RS59154B1 (sr) 2019-10-31
WO2016102562A1 (en) 2016-06-30
TW202012431A (zh) 2020-04-01
IL252438B (en) 2021-09-30
US9744213B2 (en) 2017-08-29
EP3236991A1 (en) 2017-11-01
RU2017125050A3 (enExample) 2019-06-06
US9895417B2 (en) 2018-02-20
KR102427527B1 (ko) 2022-08-01
US20170182124A1 (en) 2017-06-29
SI3236991T1 (sl) 2019-09-30
DK3236991T3 (da) 2019-08-26
TWI681966B (zh) 2020-01-11
JP2018505146A (ja) 2018-02-22
RU2017125050A (ru) 2019-01-25
PT3236991T (pt) 2019-09-06
MX377044B (es) 2025-03-07
AR103246A1 (es) 2017-04-26
EP3236991B1 (en) 2019-06-19
AU2015371056A1 (en) 2017-06-15
TW201632545A (zh) 2016-09-16
IL252438A0 (en) 2017-07-31
US20170354713A1 (en) 2017-12-14
AU2015371056B2 (en) 2020-06-25
CN107108709A (zh) 2017-08-29
ES2742503T3 (es) 2020-02-14
BR112017011552A2 (pt) 2018-02-14
HK1246156B (en) 2020-03-27
US10124039B2 (en) 2018-11-13
CN107108709B (zh) 2021-12-14
ZA201703768B (en) 2020-05-27
HRP20191292T1 (hr) 2019-10-18
MY181181A (en) 2020-12-21
SA517381673B1 (ar) 2020-10-29

Similar Documents

Publication Publication Date Title
KR102427527B1 (ko) Fgf21 유도체 및 그것의 용도
HK1246156A1 (en) Fgf21 derivatives and uses thereof
US20240066132A1 (en) Novel fatty acids and their use in conjugation to biomolecules
ES2692495T3 (es) Derivados del FGF21 con aglutinante de albúmina A-B-C-D-E- y sus usos
US20230364248A1 (en) Mic-1 compounds and uses thereof
JP5931857B2 (ja) 追加のジスルフィド結合を含有するインスリン誘導体
JP2013533227A (ja) Ｆｇｆ２１類似体および誘導体
KR20130028053A (ko) 장기적 생체 내 효능을 갖는 성장 호르몬
ES2805326T3 (es) Coagonistas estables del receptor de GLP-1/glucagón basados en GLP-1
KR20080016674A (ko) 트랜스글루타미나제 매개 성장 호르몬 컨쥬게이션
CA2972128C (en) Fgf21 derivatives and uses thereof
BR112017011552B1 (pt) Derivados de uma proteína do fgf21 e uso terapêutico e/ou profilático dos mesmos